Literature DB >> 21523365

Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies.

Malgorzata E Krzyszczak1, Yi Li, Steven J Ross, Angela Ceribelli, Edward K L Chan, Michael R Bubb, Eric S Sobel, Westley H Reeves, Minoru Satoh.   

Abstract

Autoantibodies to topoisomerase I (topo I), RNA polymerase III (RNAPIII), centromere, U3RNP/fibrillarin, Th, PM-Scl, and U1RNP found in scleroderma (SSc) are associated with unique clinical subsets. The effects of race and gender on autoantibody prevalence and clinical manifestations were examined. Autoantibodies in sera from 105 SSc (include 75 Caucasian, 24 African-American, 6 others; 89 females and 16 males) were analyzed by immunofluorescence and immunoprecipitation. Clinical information was from database. SSc-related autoantibodies seldom coexist except for anti-topo I and anti-U1RNP. Anti-topo I (35% vs 15%), anti-U3RNP (30% vs 3%, p = 0.0005), and anti-U1RNP (30% vs 13%) were more common in African-Americans vs Caucasians. Anti-centromere (17%) and anti-PM-Scl (only in 8% of female) were found only in Caucasians. In race/gender combination, all three African-American males had anti-topo I (p = 0.04). Anti-U3RNP (35% vs 3%, p = 0.0005) and anti-U1RNP were common in African-American females. In African-American, all nucleolar dominant staining sera had anti-U3RNP; nuclear pattern was topo I (50%), U1RNP (19%), and RNAPIII (13%). In Caucasian, nucleolar was anti-Th (43%) and PM-Scl (29%); nuclear pattern was RNAPIII (29%), topo I (24%), and U1RNP (18%). Anti-topo I, anti-RNAPIII, and anti-U3RNP were associated with diffuse SSc while anti-centromere, anti-Th, and anti-U1 with limited disease. Proximal scleroderma was less common in African-American with anti-topo I (38% vs 91% in Caucasian, p = 0.04). The production of SSc-related autoantibodies is gender and race dependent, and this can be highly relevant in understanding their clinical significance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21523365      PMCID: PMC3629275          DOI: 10.1007/s10067-011-1751-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  31 in total

1.  Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies.

Authors:  Yoshioki Yamasaki; Minna Honkanen-Scott; Liza Hernandez; Keigo Ikeda; Tolga Barker; Michael R Bubb; Sonali Narain; Hanno B Richards; Edward K L Chan; Westley H Reeves; Minoru Satoh
Journal:  Arthritis Rheum       Date:  2006-09

2.  Anti-topoisomerase I antibodies in systemic lupus erythematosus as a marker of severe nephritis.

Authors:  Mohamed A Hamidou; Marie A Audrain; Agathe Masseau; Christian Agard; Anne Moreau
Journal:  Clin Rheumatol       Date:  2006-03-07       Impact factor: 2.980

3.  Serologic profile and mortality rates of scleroderma renal crisis in Italy.

Authors:  Veronica Codullo; Ilaria Cavazzana; Claudia Bonino; Claudia Alpini; Lorenzo Cavagna; Franco Cozzi; Nicoletta Del Papa; Franco Franceschini; Serena Guiducci; Gabriella Morozzi; Amelia Ruffatti; Clodoveo Ferri; Roberto Giacomelli; Marco Matucci-Cerinic; Gabriele Valentini; Carlomaurizio Montecucco
Journal:  J Rheumatol       Date:  2009-06-01       Impact factor: 4.666

4.  Antinuclear antibodies in scleroderma, mixed connective tissue disease and "primary" Raynaud's phenomenon.

Authors:  M Cruz; G Mejia; C Lavalle; J J Cortes; P A Reyes
Journal:  Clin Rheumatol       Date:  1988-03       Impact factor: 2.980

Review 5.  Anti-Scl-70 (topo-I) antibodies in SLE: Myth or reality?

Authors:  Michael Mahler; Earl D Silverman; Johannes Schulte-Pelkum; Marvin J Fritzler
Journal:  Autoimmun Rev       Date:  2010-06-22       Impact factor: 9.754

6.  Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis.

Authors:  Y Okano; T A Medsger
Journal:  Arthritis Rheum       Date:  1990-12

7.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

8.  Scl 70 antibody--a specific marker of systemic sclerosis.

Authors:  M Jarzabek-Chorzelska; M Blaszczyk; S Jablonska; T Chorzelski; V Kumar; E H Beutner
Journal:  Br J Dermatol       Date:  1986-10       Impact factor: 9.302

Review 9.  Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies.

Authors:  Michelle L Harris; Antony Rosen
Journal:  Curr Opin Rheumatol       Date:  2003-11       Impact factor: 5.006

10.  Anti-RNA polymerase III antibodies: a marker of systemic sclerosis with rapid onset and skin thickening progression.

Authors:  Ilaria Cavazzana; Angela Ceribelli; Ceribelli Angela; Paolo Airo'; Airo' Paolo; Stefania Zingarelli; Zingarelli Stefania; Angela Tincani; Tincani Angela; Franco Franceschini; Franceschini Franco
Journal:  Autoimmun Rev       Date:  2009-02-09       Impact factor: 9.754

View more
  19 in total

1.  A new immunoprecipitation-real time quantitative PCR assay for anti-Th/To and anti-U3RNP antibody detection in systemic sclerosis.

Authors:  Angela Ceribelli; Minoru Satoh; Edward K L Chan
Journal:  Arthritis Res Ther       Date:  2012-05-29       Impact factor: 5.156

2.  Detection of anti-U3-RNP/fibrillarin IgG antibodies by line immunoblot assay has comparable clinical significance to immunoprecipitation testing in systemic sclerosis.

Authors:  Lisa K Peterson; Troy D Jaskowski; Maureen D Mayes; Anne E Tebo
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

3.  Clinical and serological features of systemic sclerosis in a Chinese cohort.

Authors:  Jiucun Wang; Shervin Assassi; Gang Guo; Wenzhen Tu; Wenyu Wu; Li Yang; Rong Xiao; Yongqiang Zhao; Haiyan Chu; Jie Liu; Yanyun Ma; Sarah J Kim; Li Jin; Maureen D Mayes; Hejian Zou; Xiaodong Zhou
Journal:  Clin Rheumatol       Date:  2012-12-28       Impact factor: 2.980

4.  A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, New Zealand.

Authors:  Winston S J Chang; Joanna Schollum; Douglas H N White; Kamal K Solanki
Journal:  Clin Rheumatol       Date:  2015-05-29       Impact factor: 2.980

5.  Clinical and laboratory features of African-Brazilian patients with systemic sclerosis.

Authors:  Cristiane Mendes; Vilma S T Viana; Sandra G Pasoto; Elaine P Leon; Eloisa Bonfa; Percival D Sampaio-Barros
Journal:  Clin Rheumatol       Date:  2019-05-07       Impact factor: 2.980

6.  Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers.

Authors:  Ilaria Cavazzana; Tamara Vojinovic; Paolo Airo'; Micaela Fredi; Angela Ceribelli; Eleonora Pedretti; Maria Grazia Lazzaroni; Emirena Garrafa; Franco Franceschini
Journal:  Clin Rev Allergy Immunol       Date:  2022-06-18       Impact factor: 8.667

Review 7.  Clinical Significance of Antinucleolar Antibodies: Biomarkers for Autoimmune Diseases, Malignancies, and others.

Authors:  Minoru Satoh; Angela Ceribelli; Tomoko Hasegawa; Shin Tanaka
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-08       Impact factor: 10.817

8.  Survival rate, causes of death, and risk factors in systemic sclerosis: a large cohort study.

Authors:  Xue Li; Yu-Quan Qian; Na Liu; Rong Mu; Yu Zuo; Guo-Chun Wang; Yuan Jia; Zhan-Guo Li
Journal:  Clin Rheumatol       Date:  2018-09-18       Impact factor: 2.980

9.  Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma.

Authors:  Yoshinao Muro; Yuji Hosono; Kazumitsu Sugiura; Yasushi Ogawa; Tsuneyo Mimori; Masashi Akiyama
Journal:  Arthritis Res Ther       Date:  2015-03-11       Impact factor: 5.156

10.  Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay.

Authors:  Michael Mahler; Cristina Gascon; Sima Patel; Angela Ceribelli; Marvin J Fritzler; Andreas Swart; Edward K L Chan; Minoru Satoh
Journal:  Arthritis Res Ther       Date:  2013-04-12       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.